Background: Due to the premium rate of Chronic Kidney Disease (CKD), we have increased our knowledge according to diagnosis and treatment of Bone Mineral Disease (BMD) problems in End-Stage Renal Disease (ESRD). Currently, various treatment options are available. Medication used for Secondary Hyper-Parathyroidism (SHPT) give promising results not only in regulation of Ca, P and Parathormone levels but also in anemia parameters improving among others life quality. Materials and Methods: A retrospective observational study was conducted in a Chronic Hemodialysis Unit. One-hundred ESRD patients were recruited for twenty-four months. Biochemical parameters were related to medication prescribed and the prognostic value was estimated. Cinacalcet was administrated to 43 out of 100 patients in a dose of 30-120 mg. Results: Significant differences were observed in PTH, Ca and P levels with respect to Cinacalcet administration. Ca levels appeared to be higher at 30mg as compared to 60mg cinacalcet. Furthermore, a decreasing age-dependent pattern was observed with respect to cinacalcet dosage. A positive correlation was observed between dry weight (DW) and cinacalcet dose. Finally, a positive correlation between Hematocrit and Hemoglobin and cinacalcet was manifested. Conclusions: Cinacalcet, is a potential cardiovascular and bone protective agent, which is approved in ESRD patients to assist SHPT. A novel information occurred from this study, which had to do with the improvement of the control of anemia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.